Evidence map›Paper›PMID 26187412›Full record

ArticleImmunity2015

Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.

Jessica L Halliley, Christopher M Tipton, Jane Liesveld, Alexander F Rosenberg, Jaime Darce, Ivan V Gregoretti, Lana Popova, Denise Kaminiski, Christopher F Fucile, Igor Albizua and 14 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04372615 (A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease), which is not on this map. Cited by 322 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
322citing papers in PubMed, 3 pooled it
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04372615 phase2recruitingnot on this mapstarted 2022, after this paper: background citation

A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease

TypeinterventionalSponsorUniversity of UtahRan2022 to 2028Enrolled116ConditionsAutoimmune Encephalitis, EncephalitisArmsInebilizumab, Placebo
3 · Its place in the literature

Who cites it

322 citing papers in PubMed, 3 syntheses or guidelines pooled it, 523 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

262 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 1 country.

Jessica L HallileyDivisions of Pulmonary, Allergy, & Critical Care Medicine, Emory University, Atlanta, GA 30322, USA; Pulmonary & Critical Care Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.
Christopher M TiptonDivision of Rheumatology, Emory University, Atlanta, GA 30322, USA; Lowance Center for Human Immunology in the Departments of Medicine and Pediatrics, Emory University, Atlanta, GA 30322, USA.
Jane LiesveldDivisions of Hematology/Oncology/James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA.
Alexander F RosenbergDivision of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Jaime DarceCell Signaling Technology, Inc., Danvers, MA 01923, USA.
Ivan V GregorettiCell Signaling Technology, Inc., Danvers, MA 01923, USA.
Lana PopovaCell Signaling Technology, Inc., Danvers, MA 01923, USA.
Denise KaminiskiDivision of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Christopher F FucileDivision of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Igor AlbizuaDivisions of Pulmonary, Allergy, & Critical Care Medicine, Emory University, Atlanta, GA 30322, USA.
Shuya KyuDivisions of Pulmonary, Allergy, & Critical Care Medicine, Emory University, Atlanta, GA 30322, USA.
Kuang-Yueh ChiangDepartment of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA 30322, USA.
Kyle T BradleyDepartment of Pathology & Laboratory Medicine, Emory University, Atlanta, GA 30322, USA.
Richard BurackDepartment of Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Mark SlifkaOregon Health & Sciences University, Beaverton, OR 97006, USA.
Erika HammarlundOregon Health & Sciences University, Beaverton, OR 97006, USA.
Hao WuDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, GA 30322, USA.
Liping ZhaoDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, GA 30322, USA.
Edward E WalshDivision of Infectious Diseases, University of Rochester Medical Center & Rochester General Hospital, Rochester, NY 14621, USA.
Ann R FalseyDivision of Infectious Diseases, University of Rochester Medical Center & Rochester General Hospital, Rochester, NY 14621, USA.
Troy D RandallDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Wan Cheung CheungCell Signaling Technology, Inc., Danvers, MA 01923, USA.
Iñaki SanzDivision of Rheumatology, Emory University, Atlanta, GA 30322, USA; Lowance Center for Human Immunology in the Departments of Medicine and Pediatrics, Emory University, Atlanta, GA 30322, USA.
F Eun-Hyung LeeDivisions of Pulmonary, Allergy, & Critical Care Medicine, Emory University, Atlanta, GA 30322, USA; Lowance Center for Human Immunology in the Departments of Medicine and Pediatrics, Emory University, Atlanta, GA 30322, USA. Electronic address: f.e.lee@emory.edu.
Emory University · USUniversity of Rochester Medical Center · USCell Signaling Technology (United States) · USOregon Health & Science University · USRochester General Hospital · USUniversity of Alabama at Birmingham · US

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
YR 50 PROJ- ROBERTS PRIMATE ISLETP51RR000163 · NCRR · OREGON REGIONAL PRIMATE RESEARCH CENTER · PI FRUH, KLAUS J · 1985 to 2011
$140.8M
Regulation of B cell Responses in SLE and Other Autoimmune DiseasesU19AI110483 · NIAID · EMORY UNIVERSITY · PI JEREMY M. BOSS · 2014 to 2026
$76.6M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Virus-induced Cell Fate Decisions in Anti-Viral ImmunityU19AI109962 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEE, FRANCES EUN-HYUNG · 2014 to 2018
$11.6M
Role of B Cells in Synovial Inflammation & LN Remodeling in RA ArthritisP01AI078907 · NIAID · UNIVERSITY OF ROCHESTER · PI WU, HULIN · 2010 to 2014
$10.8M
Translational Research Project Effector and Regulatory B cells in SLEU19AI056390 · NIAID · UNIVERSITY OF ROCHESTER · PI MOSMANN, TIM R. · 2003 to 2013
$8.9M
Development of a Safe and Effective Vaccine Against West Nile VirusU01AI082196 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SLIFKA, MARK K · 2009 to 2012
$7.1M
A Model System for the Study of Human B-cell ToleranceR37AI049660 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2010 to 2019
$3.7M
Pathogenesis of RSV disease in the ElderlyU01AI045969 · NIAID · UNIVERSITY OF ROCHESTER · PI WALSH, EDWARD E · 2004 to 2008
$2.5M
Central and Effector B cells in the LungR01AI097357 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RANDALL, TROY D · 2012 to 2016
$1.8M
NCATS NIH HHS UL1 TR000454NCI NIH HHS P30 CA013148NCRR NIH HHS P51 RR000163NIAID NIH HHS AI049600NIAID NIH HHS AI078907NIAID NIH HHS ARRA:AI056390-06S2NIAID NIH HHS HHSN266200500030CNIAID NIH HHS K23 AI067501NIAID NIH HHS K23 AI67501NIAID NIH HHS L30 AI057621NIAID NIH HHS N01 AI050029NIAID NIH HHS N01-AI50029NIAID NIH HHS P01 AI078907NIAID NIH HHS R01 AI049660NIAID NIH HHS R01 AI097357NIAID NIH HHS R21 AI094218NIAID NIH HHS R21AI094218NIAID NIH HHS R21 AI109601NIAID NIH HHS R21AI109601NIAID NIH HHS R37 AI049660NIAID NIH HHS R37AI049660NIAID NIH HHS U01 AI045969NIAID NIH HHS U01AI045969NIAID NIH HHS U01 AI082196NIAID NIH HHS U19 AI056390NIAID NIH HHS U19 AI109962NIAID NIH HHS U19 AI110483NIAID NIH HHS UO1AI082196NIH HHS 8P51OD011092-53NIH HHS P51 OD011092PHS HHS P01A1078907
6 · The paper itself

Abstract

Antibody responses to viral infections are sustained for decades by long-lived plasma cells (LLPCs). However, LLPCs have yet to be characterized in humans. Here we used CD19, CD38, and CD138 to identify four PC subsets in human bone marrow (BM). We found that the CD19(-)CD38(hi)CD138(+) subset was morphologically distinct, differentially expressed PC-associated genes, and exclusively contained PCs specific for viral antigens to which the subjects had not been exposed for more than 40 years. Protein sequences of measles- and mumps-specific circulating antibodies were encoded for by CD19(-)CD38(hi)CD138(+) PCs in the BM. Finally, we found that CD19(-)CD38(hi)CD138(+) PCs had a distinct RNA transcriptome signature and human immunoglobulin heavy chain (VH) repertoire that was relatively uncoupled from other BM PC subsets and probably represents the B cell response's "historical record" of antigenic exposure. Thus, our studies define human LLPCs and provide a mechanism for the life-long maintenance of anti-viral antibodies in the serum.

Indexed as

ADP-ribosyl Cyclase 1AdultAgedAntibodies, ViralAntigens, CD19Bone Marrow CellsHumansImmunoglobulin Heavy ChainsMeasles virusMembrane GlycoproteinsMiddle AgedMumps virusPlasma CellsRNA, MessengerSyndecan-1Young AdultADP-ribosyl Cyclase 1Antibodies, ViralAntigens, CD19CD38 protein, humanImmunoglobulin Heavy ChainsMembrane GlycoproteinsRNA, MessengerSDC1 protein, humanSyndecan-1antibody secreting cellsbone marrowheterogeneityhumanlong-lived plasma cellsmeaslesmumps infectionnext generation sequencingplasmablastsplasma cellsproteomicsvaccine

Identifiers

PMID26187412
PMCPMC4680845
OpenAlexW1550723234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.